TBIO

Translate Bio, Inc.
CAPPED RATING

Translate Bio, Inc. engages in the research and development of therapeutic drugs. It focuses on developing medicines to treat diseases caused by protein or gene dysfunction. Its lead product candidates include MRT5005 for the treatment of cystic fibrosis; and for the treatment of ornithine transcarbamylase deficiency. The company was founded by Arthur M. Krieg and Jeannie T. Lee in 2011 and is headquartered in Lexington, MA.

Translate Bio, Inc. (TBIO) is rated D+ (1.7/5) on Deltasharpe Prism, scored against General sector peers. Its strongest pillar is Value (C+); its weakest is Momentum (F). The rating has held at D+ for 265 weeks.

Quantitative Factor Evaluation • Updated

Overall Rating
1.7 / 5.0
D+
Value
C+
Factor Score 2.5 / 5.0
Growth
C
Factor Score 2.5 / 5.0
Profitability
C-
Factor Score 1.9 / 5.0
Momentum
F
Factor Score 0.2 / 5.0
Revisions
D+
Factor Score 1.5 / 5.0

Prism grades are automated quantitative screens, not buy, sell or hold recommendations, and not investment advice. Data may be delayed or contain errors. Terms

Ratings of B- and above are for members.

Register free to see every rating — your first 2 weeks of Premium are on us.

Register — 2 weeks free

Underlying Financial Metrics

P/E Ratio N/A
EV / EBITDA N/A
Rev Growth YoY 9.3%
Gross Margin 0.0%
Price Return 3M -98.0%
Price Return 12M -95.0%
Catalyst Signal 0.00
Market Cap N/A
TTM Revenue N/A
Price / Sales N/A
ROE 4.2%

Historical Factor Score Progression

Held D+ for 265 weeks
Date Value Growth Profitability Momentum Revisions Overall
2026-07-29 C+ (2.5) C (2.5) C- (1.9) F (0.2) D+ (1.5) D+ (1.7)
2021-06-30 C+ (2.5) C- (1.9) D+ (1.8) D- (1.0) D (1.5) D+ (1.7)
2021-03-31 C+ (2.5) F (0.4) C- (1.9) D- (1.0) D (1.5) D (1.5)
2020-12-31 C+ (2.5) D- (1.0) D+ (1.8) D- (1.0) D (1.5) D+ (1.6)
2020-09-30 C+ (2.5) C+ (2.5) C- (1.9) D- (1.0) D (1.4) C- (1.9)